Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common period drug double as an anaemia fix?

NCT ID NCT06519422

Disease control Sponsor: London School of Hygiene and Tropical Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This trial tests whether adding tranexamic acid (TXA) to standard iron and vitamin supplements helps treat anaemia in menstruating women better than supplements alone. Anaemia, caused by monthly blood loss, can lead to fatigue and complications in pregnancy. The study will include 4,000 women with anaemia and measure changes in hemoglobin levels after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tranexamic acid (TXA) tablets taken alongside usual iron and vitamin supplements
What this could lead to
If it works, adding tranexamic acid to iron supplements could offer a more effective way to treat anaemia in women with heavy periods, improving energy and reducing pregnancy-related risks.
What could go wrong
This is a large trial, but results are not yet known. Tranexamic acid may not add benefit over iron alone, and it carries risks like blood clots, though these are rare.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 4,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult women aged 18 years and older. * Currently menstruating, with menstrual periods occurring at least every 38 days and lasting ≥2 days. * Anaemia at screening, defined as hemoglobin (Hb) \<120 g/L by point-of-care finger prick test. * Willing and able to provide informed consent. * Able to attend in-person follow-up visits during the trial period. Individuals with known thalassaemia and sickle cell disease are eligible to participate and take the trial treatment but will not be given standard of care iron supplementation unless it is prescribed by their own treating clinician. They will continue to receive their usual standard care. Exclusion Criteria: * Planning to get pregnant during the trial period * Already taking TXA * Known to have possible contraindications to TXA treatment (including allergy to TXA or its excipients, renal impairment, active thromboembolic disease, history of venous or arterial thrombosis, history of convulsion.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia Hemorrhage Iron Deficiencies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anaemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mbeya College of Health and Allied Sciences, University of Dar es Salaam

    NOT_YET_RECRUITING

    Mbeya, Tanzania

  • Shifa Tameer e Millat University

    NOT_YET_RECRUITING

    Islamabad, Pakistan

  • University College Hospital

    RECRUITING

    Ibadan, Oyo State, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.